| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Elkind, Flint, and Sacco) and Medicine (Dr. Sciacca), Columbia University College of Physicians and Surgeons, New York, NY; Gertrude H. Sergievsky Center (Drs. Elkind and Sacco), Columbia University, New York, NY; Department of Epidemiology (Dr. Sacco), Joseph Mailman School of Public Health, New York, NY.
Address correspondence and reprint requests to Dr. Mitchell S.V. Elkind, Neurological Institute, Room 547, 710 West 168th Street, New York, NY 10032; e-mail: mse13{at}columbia.edu
Background: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), the most frequently used lipid-lowering agents (LLAs) have neuroprotective effects in rodent models of ischemic stroke. The authors hypothesized that patients with ischemic stroke taking LLAs would have better outcomes than patients not taking LLAs.
Methods: The Northern Manhattan Study is a population-based study designed to determine stroke incidence and prognosis in a multiethnic, urban population. Northern Manhattan residents age 40 years or older diagnosed with their first ischemic stroke were eligible. Patients or their proxies were interviewed regarding medications being taken at home before stroke onset. The NIH Stroke Scale was used to assess stroke severity, categorized as mild (
5), moderate (6 to 13), or severe (
14), and the Barthel Index at 6 months to assess functional outcome. Clinical worsening in hospital was recorded by trial neurologists. Odds ratios and 95% CIs for association of LLA use and stroke severity, mortality, and functional outcome were calculated using logistic regression.
Results: Of 650 patients, 57 (8.8%) were taking LLAs. The majority (90.9%) of LLA users were taking a statin. Clinical worsening in hospital occurred less frequently among patients taking LLAs at stroke onset (6.3% vs 18.2%; p = 0.04). Ninety-day mortality was lower in those taking LLAs (1.8% vs 10.6%, p = 0.03). The proportion of patients with severe stroke among those taking LLAs was not lower (10.7% vs 16.8%, p = 0.39).
Conclusion: Patients taking lipid-lowering agents (LLAs) at the time of an ischemic stroke may have lower poststroke mortality and a lower risk of worsening during hospitalization. Prospective studies are warranted to determine whether LLAs, and statins in particular, have neuroprotective properties or other beneficial effects in acute ischemic stroke.
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the July 26 issue to find the title link for this article.
This article was previously published in electronic format as an Expedited E-Pub.
Received February 5, 2005. Accepted in final form April 7, 2005.
This article has been cited by other articles:
|
|
 |
|
  N. Meier, K. Nedeltchev, C. Brekenfeld, A. Galimanis, U. Fischer, O. Findling, L. Remonda, G. Schroth, H. P. Mattle, and M. Arnold Prior Statin Use, Intracranial Hemorrhage, and Outcome After Intra-Arterial Thrombolysis for Acute Ischemic Stroke Stroke, May 1, 2009; 40(5): 1729 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Romero, J. Morris, and A. Pikula Review: Stroke prevention: modifying risk factors Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 287 - 303. [Abstract] [PDF]
|
|
|
|
 |
|
 R. H. Samson The Role of Statin Drugs in the Management of the Peripheral Vascular Patient Vascular and Endovascular Surgery, August 1, 2008; 42(4): 352 - 366. [Abstract] [PDF]
|
|
|
|
|
|
M. J. Reeves, J. W. Gargano, Z. Luo, A. J. Mullard, B. S. Jacobs, A. Majid, and for the Paul Coverdell National Acute Stroke Regis Effect of Pretreatment With Statins on Ischemic Stroke Outcomes Stroke, June 1, 2008; 39(6): 1779 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Blanco, F. Nombela, M. Castellanos, M. Rodriguez-Yanez, M. Garcia-Gil, R. Leira, I. Lizasoain, J. Serena, J. Vivancos, M. A. Moro, et al. Statin treatment withdrawal in ischemic stroke: A controlled randomized study Neurology, August 28, 2007; 69(9): 904 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Y. Bang, J. L. Saver, D. S. Liebeskind, S. Starkman, P. Villablanca, N. Salamon, B. Buck, L. Ali, L. Restrepo, F. Vinuela, et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis Neurology, March 6, 2007; 68(10): 737 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Laowattana and S. M. Oppenheimer Protective effects of beta-blockers in cerebrovascular disease Neurology, February 13, 2007; 68(7): 509 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Deplanque, I. Masse, C. Lefebvre, C. Libersa, D. Leys, and R. Bordet Prior TIA, lipid-lowering drug use, and physical activity decrease ischemic stroke severity Neurology, October 24, 2006; 67(8): 1403 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Bushnell, J. Griffin, L. K. Newby, L. B. Goldstein, K. W. Mahaffey, C. A. Graffagnino, R. A. Harrington, H. D. White, R. J. Simes, R. M. Califf, et al. Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease Stroke, June 1, 2006; 37(6): 1427 - 1431. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
